We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

47 hedge funds and large institutions have $116M invested in Orchestra BioMed in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 7

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

65% more capital invested

Capital invested by funds: $70.3M → $116M (+$45.6M)

9% more funds holding

Funds holding: 43 → 47 (+4)

2.41% more ownership

Funds ownership: 37.31% → 39.72% (+2.4%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
47
Holders Change
+4
Holders Change %
+9.3%
% of All Funds
0.68%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
23
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.45M
2
State Street
State Street
Massachusetts
+$738K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$673K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$351K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$220K

Top Sellers

Rank Fund Capital Flow
1
AWA
Arkadios Wealth Advisors
Georgia
-$272K
2
GWMR
GC Wealth Management RIA
Massachusetts
-$117K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$106K
4
UBS Group
UBS Group
Switzerland
-$43.9K
5
AIG
American International Group
New York
-$37.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$45.8M – – –
PA
2
Perceptive Advisors
New York
$20.7M – – –
BlackRock
3
BlackRock
New York
$15.2M +$2.45M +423,784 +29%
Vanguard Group
4
Vanguard Group
Pennsylvania
$10.5M +$351K +60,634 +5%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$4.53M +$673K +116,119 +26%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$4.51M -$106K -18,372 -3%
State Street
7
State Street
Massachusetts
$3.12M +$738K +127,358 +50%
BC
8
Boxer Capital
California
$1.94M – – –
Charles Schwab
9
Charles Schwab
California
$1.7M +$169K +29,191 +16%
Northern Trust
10
Northern Trust
Illinois
$1.17M +$18.8K +3,250 +2%
SFG
11
SVB Financial Group
Texas
$1.04M – – –
TD Asset Management
12
TD Asset Management
Ontario, Canada
$755K – – –
IA
13
IFP Advisors
Florida
$612K +$92.6K +15,986 +27%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$576K +$220K +37,906 +116%
LM
15
Lasry Marc
$496K – – –
HighTower Advisors
16
HighTower Advisors
Illinois
$416K -$11.6K -2,000 -4%
Manulife (Manufacturers Life Insurance)
17
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$343K +$18.8K +3,245 +8%
N
18
Nuveen
North Carolina
$340K +$113K +19,433 +87%
RhumbLine Advisers
19
RhumbLine Advisers
Massachusetts
$215K +$101K +17,405 +193%
Jane Street
20
Jane Street
New York
$194K +$138K +23,782 New
Morgan Stanley
21
Morgan Stanley
New York
$183K +$22.2K +3,824 +20%
SIA
22
SkyView Investment Advisors
New Jersey
$163K +$116K +20,000 New
MHS
23
M Holdings Securities
Oregon
$162K +$115K +19,850 New
Bank of America
24
Bank of America
North Carolina
$129K +$65.6K +11,322 +255%
IIA
25
IPG Investment Advisors
California
$108K +$76.8K +13,250 New
1
2 3

OBIO Hedge Fund Activity: Q2 2024 in Review

47 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q2 2024, worth a combined $116M — up 65% from $70.3M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new OBIO positions and 4 closed out — a net gain of 4 holders — while 23 added to existing stakes and 7 trimmed.

The largest buyer was BlackRock, adding an estimated $2.45M. The largest seller was Arkadios Wealth Advisors, exiting entirely with an estimated $272K sold.

  • 47 institutional investors held Orchestra BioMed (OBIO) as of Q2 2024, up from 43 in Q1 2024.
  • Funds reported $116M of Orchestra BioMed stock for Q2 2024, up 65% quarter-over-quarter.
  • 8 funds opened new Orchestra BioMed positions in Q2 2024 and 4 closed out, a net change of +4 holders.
  • The largest Orchestra BioMed buyer in Q2 2024 was BlackRock, an estimated $2.45M added.
  • The largest Orchestra BioMed seller in Q2 2024 was Arkadios Wealth Advisors, an estimated $272K sold.

Based on aggregated 13F filings for Q2 2024.